TUESDAY Feb. 11, 2014, 2014 -- The U.S. Food and Drug Administration announced Tuesday that it will investigate possible links between the diabetes drug saxagliptin and a heightened risk for heart failure among users. In a statement, the ...
Tags: FDA, Diabetes Drug, Heart Failure, NEJM
Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels:UCB) today announced results from a Phase 2 trial evaluating romosozumab (AMG 785/CDP7851) in postmenopausal women with low bone mineral density (BMD). Published in the New England Journal of ...
Tags: Amgen, UCB, Phase 2 trial evaluating romosozumab, postmenopausal women